Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.410.07%
QQQ
717.380.14%
BTC/USD
79193.920.9443%
DIA
527.560.09%
GLD
398.850.22%
TLT
82.140.07%

Candel Therapeutics Inc

CADLNASDAQ
Trade with Public
Trade with Public
$12.60
-0.18-1.41%
At close: Sep 8, 5:00 PM EST
$12.72
0.120.92%
After Hours: 4:33 PM EST
OverviewNewsEventsFinancialsSentimentOwnershipCompareOptionsStock Report

Candel Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Candel Therapeutics (CADL).

Price Target Range — 8 Quarters

Analyst Consensus — 9 Analysts

8Buy
1Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+53.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026B of A SecuritiesAlec StranahanPT RaiseNeutral$9→$12
Aug 13, 2026HC Wainwright & Co.Andres Y. MaldonadoMaintainedBuy$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating

Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and raises the price target from $22 to $26.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $22

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $24 to $22.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved